Psychedelics and ketamine as plasticity openers, not magic cures

September 29, 2026 · 23 min read

Ketamine, psilocybin and MDMA work through different receptors, yet the sources describe each as opening a temporary window of neuroplasticity that therapy and practice must then use. It explains why effects fade without integration and why a neurosurgeon calls drugs, not electrodes, today's best plasticity tool.

12 questions on this insight. Answer in your head, then open the card.
What is the common point about ketamine, psilocybin and MDMA? Show answer

Each starts a process of brain change. Lasting benefit depends on therapy, integration and behavior afterward.

What receptors does each drug act on? Show answer

Ketamine blocks NMDA receptors, psilocybin activates serotonin 2A receptors, and MDMA releases serotonin and dopamine and acts largely through serotonin 1B.

How can ketamine block a plasticity receptor and still create plasticity? Show answer

It blocks NMDA receptors on inhibitory neurons, freeing mood circuits to fire in bursts that release BDNF and drive rewiring.

How long does a single ketamine treatment last? Show answer

Relief usually wears off after about three days to a week unless sessions are repeated.

What did the naltrexone study show? Show answer

With opioid receptors blocked, patients still felt ketamine's euphoria and dissociation but lost the antidepressant effect.

What is Huberman's wedge image? Show answer

Psychedelics are a wedge under the boulder of neuroplasticity. The person's conscious effort decides whether it rolls in a useful direction.

Why is plasticity not automatically good? Show answer

Brain injury and methamphetamine also rewire the brain, in harmful ways.

What does Huberman say about MDMA and PTSD? Show answer

MDMA taken on its own does not cure PTSD. It augments talk therapy, with preparation and integration sessions around dosing.

Where does Robin Carhart-Harris differ in emphasis from Huberman? Show answer

He holds that the experience itself drives healing, since its strength and the patient's trust predict outcomes.

What does Carhart-Harris say about relapse after psilocybin? Show answer

In treatment-resistant depression, relapse by three months is more the rule than the exception.

Why does Matthew MacDougall favor drugs over electrodes for plasticity? Show answer

Plasticity means changing about a trillion synapses across the brain, which a drug can reach and an electrode cannot.

Who is typically excluded from psilocybin studies? Show answer

People with or predisposed to psychosis, those with a close relative with schizophrenia or bipolar disorder, people under about 25, and pregnant or breastfeeding women.

This is the short form. The full insight has every expert's reasoning, their own words and the sources.